New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 20, 2012
10:00 EDTPANW, SIX, CLNE, CFN, UNH, MPLX, COV, BSX, MDCO, JNJ, COH, AET, TDC, RLGY, ISRGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aetna (AET) initiated with a Buy at Lazard Capital... Boston Scientific (BSX) initiated with a Buy at Stifel Nicolaus... CareFusion (CFN) initiated with a Buy at Stifel Nicolaus... Coach (COH) initiated with an Outperform at Wells Fargo... Covidien (COV) initiated with a Buy at Brean Capital... Intuitive Surgical (ISRG) initiated with a Hold at Stifel Nicolaus... Johnson & Johnson (JNJ) initiated with a Hold at Stifel Nicolaus... MPLX (MPLX) initiated with a Neutral at UBS... Realogy (RLGY) initiated with a Neutral at Goldman... The Medicines Co. (MDCO) initiated with an Outperform at Oppenheimer... UnitedHealth (UNH) initiated with a Buy at Lazard Capital... Teradata (TDC) initiated with an Outperform at Credit Suisse... Six Flags (SIX) initiated with a Neutral at Longbow... Palo Alto (PANW) initiated with a Neutral at Nomura... Clean Energy (CLNE) initiated with a Buy at Dougherty.
News For AET;BSX;CFN;COH;COV;ISRG;JNJ;MPLX;RLGY;MDCO;UNH;TDC;SIX;PANW;CLNE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 22, 2015
07:13 EDTISRGIntuitive Surgical upgraded to Buy at Canaccord
As reported previously, Canaccord upgraded Intuitive Surgical to Buy from Hold citing accelerated growth and improving gross margins. Canaccord raised its price target to $615 from $517 on Intuitive Surgical shares.
07:01 EDTISRGIntuitive Surgical price target raised to $675 from $616 at Jefferies
Jefferies raised its price target for Intuitive Surgical to $675 calling the company's Q2 results strong "across the board." Intuitive's upped guidance shows the positive trends are sustainability, the firm tells investors in a research note. It keeps a Buy rating on the name.
06:53 EDTISRGIntuitive Surgical upgraded to Buy from Hold at Canaccord
Subscribe for More Information
06:00 EDTISRGIntuitive Surgical price target raised to $625 from $575 at Barclays
Barclays analyst Matthew Taylor raised his price target for Intuitive Surgical to $625 saying the company's Q2 results should ease investor concerns around procedure growth and margins. The analyst calls the quarter "excellent" in a research note titled "Hitting All Cylinders." Taylor keeps an Overweight rating on the stock.
July 21, 2015
19:00 EDTISRGOn The Fly: After Hours Movers
Subscribe for More Information
16:59 EDTISRGIntuitive Surgical advances further to up over 12% in after-hours trading
16:58 EDTISRGIntuitive Surgical sees 2H15 gross profit margin 67%-68%
Subscribe for More Information
16:57 EDTISRGIntuitive Surgical raises 2015 procedural growth view to 11%-13% from 8%-11%
Comments from company's Q2 earnings conference call.
16:43 EDTISRGIntuitive Surgical advances almost 9% after reporting Q2 results
Subscribe for More Information
16:08 EDTISRGIntuitive Surgical Q2 worldwide da Vinci procedures grew 14%
Worldwide da Vinci procedures grew approximately 14% over the second quarter of 2014, up 8% sequentially over the first quarter of 2015, driven primarily by growth in U.S. general surgery procedures and broad-based procedure growth in Asia and other international markets. The Company shipped 118 da Vinci Surgical Systems, compared to 96 in the second quarter of 2014 and 99 in the first quarter of 2015.
16:07 EDTISRGIntuitive Surgical reports Q2 EPS $4.57, consensus $3.98
Subscribe for More Information
15:02 EDTISRGNotable companies reporting after market close
Subscribe for More Information
14:16 EDTISRGIntuitive Surgical July weekly 502.50 straddle priced for 6.4% movement into Q2
Subscribe for More Information
12:33 EDTISRGEarnings Watch: Intuitive Surgical down about 9% since last earnings
Subscribe for More Information
12:16 EDTISRGIntuitive Surgical technical comments before results
The stock has been trading in a sideways range from $480 at the low and $512 at the high since April of this year. Those two bounds may help us understand where price may go following earnings. If the news is bearish, a breakdown below $480 would resolve the range bearishly. Next supports to watch as potential downside objectives would be at $475, $470.79, and $467.45. If the news is a bullish surprise, the upper bound of the range at $512 would likely be tested. A breakout above $512 would resolve the range bullishly. Next resistance levels to watch as potential upside objectives would be at $525.57, $538.83, and $542.41.
09:00 EDTMPLXMPLX raises quarterly distribution by 7.3% to 44c per unit
Subscribe for More Information
08:30 EDTISRGIntuitive Surgical July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
07:22 EDTBSXBoston Scientific should be bought on pullbacks, says RBC Capital
RBC Capital expects Boston Scientific to report slightly higher than expected Q2 EPS and in-line revenue. The firm expects the company's results to be boosted by strength in ICDs and OUS DES stents. RBC is confident that the company's EPS can grow by low teen percentage levels over the long-term and recommends buying the shares on pullbacks.
July 20, 2015
09:08 EDTBSXBoston Scientific begins study of resorbable drug-eluting scaffold system
Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study, or FAST, is a prospective, single arm study designed to assess the safety and performance of this next generation scaffold for the treatment of atherosclerotic coronary lesions.
07:11 EDTMPLXMPLX, MarkWest Energy provide supplimental information about merger
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use